The Phase 3 Efficacy and Safety Study of GTX-102 (ASO) in Pediatrics, sponsored by Ultragenyx, is now listed on ClinicalTrials.gov.
Interested in learning more? ASF and FAST will be hosting a community webinar about the trial, named Aspire, with the Ultragenyx team on Oct 23, 2024 at 1:00pm EST.